What Suven Pharmaceuticals does

Suven Pharmaceuticals, operating under the rebranded name Cohance Lifesciences Limited, is an Indian public-listed contract development and manufacturing organization (CDMO) serving global pharmaceutical and biotechnology innovators. The company is incorporated in Maharashtra (CIN: L24299MH2018PLC422236) with its operating base in Hyderabad, employs 1,001–5,000 people, and is listed on the NSE under the symbol SUVENPHAR. Cohance positions itself as a multi-modality CDMO platform built around three technology pillars: small molecule active pharmaceutical ingredients (APIs), antibody-drug conjugates (ADCs), and nucleic acid chemistry. Its technical differentiation rests on specialized capabilities including phosphoramidite chemistry, nucleoside modification, ADC payload development, and bioconjugation, delivered from multiple USFDA- and EDQM-accredited manufacturing sites and supported by PhD-staffed R&D centers.

The business operates a project-based B2B engagement model under which innovator customers contract Cohance for development and manufacturing services spanning the full lifecycle from discovery and process development through clinical and commercial supply. Service lines include end-to-end CDMO services, API+ & Formulations, and Clinical & Analytical Services, with downstream offerings in generic APIs, specialty chemicals (agrochemicals), and ADC payloads. Customer segmentation is horizontal, dividing the market into pharmaceutical innovators (primary segment) and generic pharmaceutical companies (secondary), with both served through direct enterprise field sales. Long-term customer relationships are emphasized via a tracked "average partnership years" metric. In 2024 the company executed an aggressive M&A program, acquiring Sapala Organics, Casper Pharma, and NJ Bio to deepen its nucleic acid, generic formulations, and biologic/ADC-adjacent capabilities, while simultaneously rebranding to Cohance Lifesciences to signal its transition from a single-modality API manufacturer into an integrated multi-modality CDMO platform. The company is also investing in ESG credentials (Ecovadis Gold, SBTi validation, CDP B rating) that are increasingly required to qualify for multinational pharma vendor lists.

Name

Suven Pharmaceuticals

Legal name

Cohance Lifesciences Limited

Website

https://suvenpharm.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Short description

Cohance Lifesciences (formerly Suven Pharmaceuticals) is an Indian public-listed CDMO serving global pharma and biotech innovators across three modalities: small molecule APIs, antibody-drug conjugates, and nucleic acid chemistry, with USFDA- and EDQM-accredited manufacturing and a multi-modality platform built partly through 2024 acquisitions.

Ownership category

akta.pro rank

Product category

Contract Pharmaceutical Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Contract pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Antibody drug conjugates
• Nucleic acid chemistry
• Drug substance development

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. CDMO Services: Contract development and manufacturing services for pharmaceutical innovators. Revenue is generated through project-based contracts for development and manufacturing of APIs, ADCs, and nucleic acid chemistries. The company serves both innovator relationships and commercial molecules, indicating a mix of early-stage development fees and commercial manufacturing revenue.
2. Generic APIs: Manufacturing and sale of generic active pharmaceutical ingredients to pharmaceutical companies.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Cohance Lifesciences (formerly Suven Pharmaceuticals Limited) is a technology-led, global CDMO platform offering integrated contract development and manufacturing services for small molecule active pharmaceutical ingredients (APIs), antibody drug conjugates (ADCs), and nucleic acid chemistry products. The company provides end-to-end capabilities spanning process research and development, clinical and commercial-scale manufacturing, formulation (API+), clinical and analytical services, and specialty chemicals and agrochemicals. It serves pharmaceutical innovators and generic pharmaceutical companies with manufacturing, licensing, and project-based engagement models.

Product overview

Cohance Lifesciences (formerly Suven Pharmaceuticals Limited) is a technology-led, global CDMO platform offering integrated contract development and manufacturing services across three core modalities: Small Molecule APIs, Antibody Drug Conjugates (ADCs), and Nucleic Acid Chemistry. The product portfolio is structured as a unified CDMO platform with service layers including CDMO Services, API+ & Formulations, and Clinical & Analytical Services. Supporting offerings include Generic APIs, Specialty Chemicals (agrochemicals), ADC Payloads, and Nucleosides & Phosphoramidites products. The platform is designed to serve innovator pharmaceutical companies with end-to-end solutions from lab to commercial supply.

Differentiator

Problem solved

Functional benefit

Products and services

• Small Molecule API CDMO Services End-to-end contract development, scale-up, and cGMP-compliant commercial manufacturing of small molecule active pharmaceutical ingredients (APIs) for global pharmaceutical innovator and generic drug companies. Covers the full lifecycle from process research and development through clinical and commercial supply.
• Antibody Drug Conjugates (ADC) CRDMO Integrated contract research, development, and manufacturing organization (CRDMO) offering for antibody drug conjugates, covering payload-linker development, bioconjugation chemistry, and drug substance manufacturing for innovator customers developing targeted oncology and other ADC therapies.
• Nucleic Acid Chemistry Services Contract development and supply of nucleic acid chemistry building blocks, including phosphoramidites and modified nucleosides, supporting oligonucleotide and nucleic acid-based therapeutic programs for innovator and generic pharmaceutical clients.
• Generic Active Pharmaceutical Ingredients Commercial sale and licensing of generic active pharmaceutical ingredients to generic and specialty pharmaceutical manufacturers, supported by regulatory filings and long-term supply agreements.
• Specialty Chemicals and Agrochemicals Manufacture and sale of specialty fine chemicals and agrochemical intermediates, leveraging the company's chemistry capabilities and manufacturing infrastructure for downstream industrial and agricultural customers.
• API+ and Formulations Integrated formulation services combining API manufacturing with finished drug product formulation, enabling customers to source combined API-plus-formulation solutions from a single contract partner.
• Clinical and Analytical Services Clinical-stage and analytical services supporting bioavailability and bioequivalence studies alongside pharmaceutical development programs for innovator and generic pharmaceutical customers.
• ADC Payloads Specialized manufacture of cytotoxic payloads and payload-linker intermediates used in antibody drug conjugate construction, supplied to innovator customers developing ADC therapies.
• Nucleosides and Phosphoramidites Supply of nucleosides and phosphoramidite building blocks used as intermediates in nucleic acid-based therapeutic development, supplied to oligonucleotide and nucleic acid drug developers.

Quantifiable outcome

• Decades of CDMO experience with average partnership years indicating long-term customer relationships
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Pharmaceutical Supply Chain Initiative (PSCI)coreStrategic or Co-development Partner · 1 January 2013Cohance Lifesciences has been a member and supplier to PSCI since 2013, demonstrating commitment to ethical and sustainable supply chain practices in the pharmaceutical industry. PSCI promotes responsible stewardship and supply chain excellence.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Jubilant Pharmova: Indian pharma services company with CDMO, radiopharma, and generics operations. Direct peer across the CDMO and API offerings with similar customer base of global innovators and Indian generics players.
• Sai Life Sciences: Indian CRO-CDMO providing small molecule API development, manufacturing, and discovery services to innovator pharma. Direct peer in small-molecule CRDMO with comparable India-based manufacturing footprint and global customer base.
• Syngene International: Indian listed CRO/CDMO offering integrated drug discovery, development, and manufacturing services to global innovators. Direct peer given overlapping CDMO positioning, India footprint, and public-market comparability to Cohance.
• Piramal Pharma Solutions: CDMO arm of Piramal Group offering API development, formulation, and bioconjugation services including ADCs. Direct peer with overlapping capabilities in complex small molecules and ADCs, both serving global innovators from India.
• Divi's Laboratories: Indian listed manufacturer specializing in APIs, intermediates, and custom synthesis for global pharma. Direct peer on the small-molecule API and intermediates CDMO business with comparable USFDA-accredited manufacturing footprint.
• Laurus Labs: Indian listed manufacturer of APIs, intermediates, and formulations including ARV and oncology molecules. Direct peer on the small-molecule API and generics manufacturing business with overlapping customer segments.
• Aurigene Pharmaceutical Services: CDMO arm of Dr. Reddy's offering small molecule API development, manufacturing, and formulation services. Direct peer in India-based small molecule CDMO with comparable innovator customer engagement model.

Broad incumbents

• Catalent: Global CDMO with deep capabilities in biologics, ADCs, and softgel/oral dose manufacturing, now part of Novo Holdings. Broad incumbent that competes with Cohance across multiple modalities and offers commercial-scale capacity Cohance cannot match.
• Samsung Biologics: Korean CDMO specializing in large-scale biologics manufacturing and antibody services. Broad incumbent relevant as a competitor for ADC bioconjugation capacity and as a benchmark for commercial-scale contract manufacturing economics.
• Lonza Group: Global CDMO leader with extensive capabilities in biologics, small molecules, and ADCs. Broad incumbent operating at a much larger scale across multiple modalities, directly competing with Cohance for late-phase and commercial ADC and oligonucleotide programs.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@CohanceLifesciences
• LinkedInlinkedin.com/company/suven-pharmaceuticals
• Facebookfacebook.com/100064825007807

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Suven Pharmaceuticals